Publication | Open Access

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

UrologyGastrointestinal OncologyMedicineBiliary CancerSorafenib Versus GemcitabineSerum ProgrammeCancer TreatmentOncologyRadiation OncologyCancer Research